May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Requirement of Intact Sympathetic Transmission for the Ocular Hypotensive Effect of Melatonin and IIK7
Author Affiliations & Notes
  • J. J. Pintor
    E.U. de Optica UCM, Madrid, Spain
    Bioquimica y Biologia Molecular IV,
  • P. Alarma-Estrany
    E.U. de Optica UCM, Madrid, Spain
    Bioquimica y Biologia Molecular IV,
  • A. Mediero
    E.U. de Optica UCM, Madrid, Spain
    Bioquimica y Biologia Molecular IV,
  • A. Crooke
    E.U. de Optica UCM, Madrid, Spain
    Bioquimica y Biologia Molecular IV,
  • A. Peral
    E.U. de Optica UCM, Madrid, Spain
    Optica II,
  • Footnotes
    Commercial Relationships  J.J. Pintor, None; P. Alarma-Estrany, None; A. Mediero, None; A. Crooke, None; A. Peral, None.
  • Footnotes
    Support  This study was supported by BM05-102-0, SAF2004-06119 -C2-01, SAF2007 60835, PR1/07-14890 and RETICS 2007
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2098. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. J. Pintor, P. Alarma-Estrany, A. Mediero, A. Crooke, A. Peral; Requirement of Intact Sympathetic Transmission for the Ocular Hypotensive Effect of Melatonin and IIK7. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2098. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The aim of this study is to confirm the relationship between the ocular hypotensive effects of melatonin an the MT2 agonist IIK7, and the sympathetic nervous system that control this process.

Methods: : New Zealand white rabbits were used. Intraocular pressure (IOP) was measured by means of Tonopen®. Two IOP measurements were taken before any compound was instilled and after that once every hour for 8 hours after application of topical tetracaine. Chemical sympathectomy was performed injecting reserpine (2 mg/kg, intraperitoneally) once daily for 5 days (n=6). Control animals were injected with a similar volume of the vehicle. In another six animals, two injections of 0.2 ml of 10% 6-hydroxydopamine subconjunctival was performed. Contralateral eyes were injected with a similar volume of the vehicle. Cryostat sections of ciliary bodies were incubated with vesicular monoamine transporter (VMAT2) antibody (1:500) and then with a secondary guinea-pig IgG labelled with TRITC (1:250). After that, the tissues were observed under confocal microscopy.

Results: : When melatonin 100 µM (10 µl) was topically applied to the cornea the maximal reduction of IOP was 17.2 ± 2.0% (n=8). After melatonin application in reserpine or 6-hydroxydopamine treated animals, the values obtained were 4.7 ± 4.9 % and 5.2 ± 2.0 %, respectively. The instillation of IIK7 100 µM (10 µl) produced a reduction of 22.67 ± 4.00 %. When this analogue was topically applied after the treatment with reserpine or 6-hydroxydopamine, the reduction in IOP was 6.45 ± 2.49 % and 12.55 ± 2.00 %, respectively. The reduction it is also observed in the duration of the hypotensive effect. Immunohistochemical studies showed that non-treated animals had positive labelling for anti-VMAT2 along the ciliary processes. However, animals treated with reserpine or 6-hydroxydopamine were negative to VMAT2 antibody, indicating the success in the chemical sympathectomy.

Conclusions: : The ocular hypotensive effects of melatonin and IIK7 are coupled to the sympathetic component controlling the synthesis and drainage of the aqueous humour.

Keywords: melatonin • intraocular pressure • neurotransmitters/neurotransmitter systems 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×